EVT 401
Alternative Names: EVT-401Latest Information Update: 10 Nov 2023
At a glance
- Originator Renovis
- Developer Evotec SE; Zhejiang Conba Pharmaceutical
- Class Antirheumatics; Small molecules
- Mechanism of Action Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Immunological disorders; Inflammation
Most Recent Events
- 08 Nov 2023 EVT 401 is still in phase I trials for Inflammation and Inflammatory disorders in China, USA and Germany
- 28 Dec 2022 No development reported - Phase-I for Immunological disorders in China (PO)
- 28 Dec 2022 No development reported - Phase-I for Inflammation in China (PO)